Comparative Pharmacology
Head-to-head clinical analysis: LOTRIMIN ULTRA versus XOLEGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRIMIN ULTRA versus XOLEGEL.
LOTRIMIN ULTRA vs XOLEGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butenafine hydrochloride is a synthetic antifungal agent that inhibits the enzyme squalene epoxidase, thereby blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes, leading to fungal cell death.
Cholestyramine, the active ingredient in XOLEGEL, is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This prevents enterohepatic recirculation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver, thereby lowering serum low-density lipoprotein (LDL) cholesterol.
Adults: Apply butenafine hydrochloride 1% cream topically once daily for 7 days for tinea pedis; for tinea cruris and tinea corporis, apply once daily for 14 days.
Apply a thin layer to affected areas once daily. Maximum 60 g per week. Do not use on the face, axillae, or groin. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal elimination half-life is approximately 24-48 hours (range 20-50 hours), supporting once-daily topical application.
The terminal elimination half-life is approximately 2.5 hours in adults based on intravenous data, but clinical relevance is minimal due to negligible systemic absorption after topical use.
Primarily fecal (approx. 80%) as unchanged drug and metabolites; renal excretion accounts for <10% of the dose.
Following topical application, negligible systemic absorption occurs; any absorbed fraction is primarily eliminated via renal excretion as unchanged drug and metabolites. Biliary/fecal excretion is minimal.
Category C
Category C
Topical Antifungal
Topical Antifungal